Gonorrhea – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Gonorrhea – Pipeline Review, H1 2018’, provides an overview of the Gonorrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gonorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gonorrhea

– The report reviews pipeline therapeutics for Gonorrhea by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gonorrhea therapeutics and enlists all their major and minor projects

– The report assesses Gonorrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gonorrhea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gonorrhea

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gonorrhea pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Debiopharm International SA

Entasis Therapeutics Inc

Merck & Co Inc

Recce Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gonorrhea Overview

Gonorrhea Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gonorrhea Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gonorrhea Companies Involved in Therapeutics Development

Debiopharm International SA

Entasis Therapeutics Inc

Merck & Co Inc

Recce Ltd

Gonorrhea Drug Profiles

BCP-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1453 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edodekin alfa SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GvaX-12 SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zoliflodacin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gonorrhea Dormant Projects

Gonorrhea Discontinued Products

Gonorrhea Product Development Milestones

Featured News & Press Releases

Jul 25, 2017: Debiopharm International Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

Oct 28, 2016: Entasis Therapeutics to Present Data on ETX0914 at IDWeek 2016

Sep 21, 2016: Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea

Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents

Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies

Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection

Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID

Oct 04, 2012: Cempra Announces Positive Top-Line Results From Solithromycin Phase II Clinical Trial In Patients With Uncomplicated Urogenital Gonorrhea

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gonorrhea, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Gonorrhea Pipeline by Debiopharm International SA, H1 2018

Gonorrhea Pipeline by Entasis Therapeutics Inc, H1 2018

Gonorrhea Pipeline by Merck & Co Inc, H1 2018

Gonorrhea Pipeline by Recce Ltd, H1 2018

Gonorrhea Dormant Projects, H1 2018

Gonorrhea Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Gonorrhea, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports